Actively Recruiting
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Led by Stanford University · Updated on 2025-08-07
148
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
Sponsors
S
Stanford University
Lead Sponsor
T
The Leukemia and Lymphoma Society
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and duration of response (DOR). An evaluable participant is one who completes leukapheresis, lymphodepleting chemotherapy and CART infusion.
CONDITIONS
Official Title
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Histologically confirmed diagnosis of one of the specified B Cell Lymphomas
- Relapsed or refractory disease after at least two lines of systemic therapy, including anti-CD20 monoclonal antibody unless CD20 negative
- Measurable disease or specific disease markers as defined per lymphoma type
- Availability of tissue for CD22 expression analysis or willingness to undergo biopsy
- At least 100 days post prior stem cell transplant with no graft versus host disease and off immunosuppressive drugs for at least 30 days
- Stable or resolved toxicities from prior therapies
- Adequate performance status (ECOG 0-2 or Karnofsky >60%)
- Adequate organ and marrow function including specified blood counts and organ measures
- Females of childbearing potential must have a negative pregnancy test and agree to birth control; males must agree to birth control
- Ability to provide informed consent or assent
You will not qualify if you...
- Rapidly progressive disease that may prevent completing therapy
- History or current other malignancies unless disease free or in remission as specified
- Active infections requiring intravenous antimicrobials, except simple UTI or bacterial pharyngitis responding to treatment
- Ongoing HIV, HBV, or HCV infection unless viral load undetectable
- Active neurological or autoimmune diseases affecting CNS assessment
- Recent significant cardiac events within 12 months
- Severe allergy to study agents
- Pregnant or breastfeeding
- Active primary immunodeficiency or recent autoimmune disease requiring systemic immunosuppression
- Any medical condition interfering with study safety or completion as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University
Palo Alto, California, United States, 94304
Actively Recruiting
Research Team
K
Kelly Chyan
CONTACT
K
Kendall Levine
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here